[What's new in CKD-MBD?]

Authors :: Brandenburg V
Source :: Deutsche medizinische Wochenschrift (1946) [Dtsch Med Wochenschr] 2020 Aug; Vol. 145 (16), pp. 1170-1173. Date of Electronic Publication: 2020 Aug 13.
Publication Year :: 2020
Abstract: CKD-MBD (chronic kidney disease - mineral and bone disorder) describes a complex syndrome of renal osteodystrophy, mineral disturbances and cardiovascular disease in patients with chronic kidney disease. The present articles intends to provide an up-to-date summary of recent clinically important developments in the field of CKD-MBD. The article touches specifically phosphate management, secondary hyperparathyroidism, vitamin D, arteriosclerosis, renal bone disease, and SGLT2-inhibitors. The summary also comments on which grade of evidence novel aspects and innovative developments in CKD-BMD are based. The author concludes that nephrologists should strive after more high-quality, large-scale randomized-controlled interventional trials in order to optimize the evidence behind CKD-MBD therapy.<br />Competing Interests: Vortragshonorare/Forschungsförderung von: Amgen, Bayer, BMS, Pfizer, Vifor, Resverlogix, Sanifit.<br /> (© Georg Thieme Verlag KG Stuttgart · New York.)